Tiansheng Pharmaceutical Group Co Ltd is a China-based company primarily engaged in drug R&D, production, sales, and the cultivation and processing of traditional Chinese medicinal materials. The Company's products include tablets, capsules, granules, teas, pills, and injections. Product varieties cover pediatrics, gynecology, cardiovascular system, digestive system, orthopedics, respiratory medicine, and anti-infective treatment areas. The Company's products are mainly sold to the domestic market.

Employees

1,273

Sector

Pharmaceuticals

Calendar

25/08 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
21/26/21	CN¥5.300	0.00%	19,93,750
20/26/20	CN¥5.300	+0.76%	30,80,800
19/26/19	CN¥5.260	-2.95%	31,29,550
18/26/18	CN¥5.420	+1.88%	29,39,150
17/26/17	CN¥5.320	-0.56%	13,75,900

End-of-day quote Shenzhen S.E.

More quotes

End-of-day quote Shenzhen S.E. 21/08/2026			5-day change	1st Jan Change
5.300 ^CNY	0.00%		-0.75%	+9.05%

08/05	Tiansheng Pharmaceutical Secures Proposed Selection for Three Medicines in China's National Procurement	MT
28/04	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	168.54Cr 25Cr 21Cr 20Cr 18Cr 35Cr 2.4TCr 35Cr 237.41Cr 93Cr 1.21TCr 94Cr 92Cr 3.99TCr	P/E 2024	-16.5x	P/E 2025	-27.9x
Enterprise Value	176.43Cr 26Cr 22Cr 21Cr 19Cr 36Cr 2.51TCr 37Cr 248.53Cr 97Cr 1.26TCr 99Cr 96Cr 4.17TCr	EV / Sales 2024	2.7x	EV / Sales 2025	3.16x
Free-Float	52.84%	Yield 2024 *	-	Yield 2025	-

08/05	Tiansheng Pharmaceutical Secures Proposed Selection for Three Medicines in China's National Procurement	MT
28/04	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
28/04	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/02	Three Tiansheng Pharma Drugs Set to Win Bids for China's Drug Procurement Program	MT
07/11	Tiansheng pharmaceutical and its controlling shareholder penalised, fined	RE
29/25/29	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
14/25/14	Tiansheng Pharmaceutical Group Subsidiaries Tentatively Win Bulk Drug Tenders in Guangdong	MT
15/25/15	Tiansheng Pharmaceutical Gets China Supplementary Drug Approval for Sodium Bicarbonate Injection	MT
27/25/27	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
28/25/28	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
28/25/28	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
10/25/10	Tiansheng Pharmaceutical Passes Consistency Evaluation for Antibiotic	MT
26/24/26	Chongqing Pharmaceutical Group Changsheng Pharmaceutical Co., Ltd announced that it expects to receive CNY 60 million in funding from C.Q. Pharmaceutical Holding Co., Ltd., Tiansheng Pharmaceutical Group Co., Ltd.	CI

1 week	-0.75%
Current month	+7.07%
1 month	+12.53%
3 months	-2.39%
6 months	+2.91%
Current year	+9.05%

Tiansheng Pharmaceutical Group Co., Ltd. Share Price

Stocks

002872

CNE100002QC3

Pharmaceuticals

Valuation: Tiansheng Pharmaceutical Group Co., Ltd.

Chart: Tiansheng Pharmaceutical Group Co., Ltd.

Latest news : Tiansheng Pharmaceutical Group Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Tiansheng Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	5.24	5.49
1 month	4.6	5.49
Current year	4.32	5.65
1 year	4.32	5.81
3 years	3.17	5.97
5 years	3.17	5.99
10 years	3.17	35.18

Manager	Title	Age	Since
Shuang Liu CEO	Chief Executive Officer	33	06/12/2018
Kai Sheng Wang DFI	Director of Finance/CFO	52	23/12/2013
Zonghua Tan PRN	Corporate Officer/Principal	54	11/12/2020

Director	Title	Age	Since
Shuang Liu CHM	Chairman	33	06/12/2018
Zonghua Tan BRD	Director/Board Member	54	11/12/2020
Dajian Yang BRD	Director/Board Member	66	11/12/2020

	2024	2025
Net sales	57Cr 8.47Cr 7.26Cr 6.79Cr 6.22Cr 12Cr 810.87Cr 12Cr 80Cr 31Cr 407.34Cr 32Cr 31Cr 1.35TCr	51Cr 7.65Cr 6.55Cr 6.13Cr 5.61Cr 11Cr 731.7Cr 11Cr 72Cr 28Cr 367.56Cr 29Cr 28Cr 1.22TCr
Net income	-8.74Cr -1.3Cr -1.11Cr -1.04Cr -95.39L -1.79Cr -124.4Cr -1.81Cr -12Cr -4.8Cr -62Cr -4.88Cr -4.78Cr -206.7Cr	-5.54Cr -82.45L -70.62L -66.08L -60.49L -1.14Cr -79Cr -1.15Cr -7.81Cr -3.04Cr -40Cr -3.1Cr -3.03Cr -131.07Cr
Net Debt	9.72Cr 1.45Cr 1.24Cr 1.16Cr 1.06Cr 1.99Cr 138.33Cr 2.02Cr 14Cr 5.34Cr 69Cr 5.43Cr 5.31Cr 229.84Cr	7.89Cr 1.17Cr 1.01Cr 94.11L 86.14L 1.62Cr 112.34Cr 1.64Cr 11Cr 4.34Cr 56Cr 4.41Cr 4.31Cr 186.66Cr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIANSHENG PHARMACEUTICAL GROUP CO., LTD.	0.00%	-0.75%	+8.38%	+3.31%	25Cr
ELI LILLY AND COMPANY	+0.88%	+3.84%	+77.96%	+129.75%	1,10900Cr
JOHNSON & JOHNSON	+1.07%	+3.11%	+51.11%	+56.67%	64TCr
ABBVIE INC.	+1.20%	+5.64%	+26.68%	+76.48%	46TCr
ROCHE HOLDING AG	+1.02%	+3.67%	+43.14%	+47.27%	37TCr
NOVARTIS AG	+0.85%	+2.97%	+24.48%	+42.54%	30TCr
ASTRAZENECA PLC	+1.26%	+4.54%	+2.20%	+14.84%	26TCr
AMGEN INC.	+1.88%	+5.14%	+48.20%	+67.80%	23TCr
NOVO NORDISK A/S	+1.59%	+0.87%	-12.95%	-51.91%	20TCr
GILEAD SCIENCES, INC.	+1.87%	+5.78%	+23.07%	+92.57%	18TCr
Average	+1.04%	+2.67%	+29.23%	+47.93%	37.61TCr
Weighted average by Cap.	+1.10%	+3.26%	+44.79%	+72.23%